A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
Status:
Recruiting
Trial end date:
2025-07-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effects of nivolumab when given under the
skin with or without rHuPH20.
This study will include participants with 1 of the following advanced or metastatic tumors
approved for treatment with nivolumab monotherapy:
- non-small cell lung cancer (NSCLC)
- renal cell carcinoma (RCC)
- unresectable or metastatic melanoma
- hepatocellular carcinoma (HCC)
- microsatellite instability-high or mismatch repair deficient colorectal cancer
(MSI-H/dMMR CRC)
- in Part B, other solid tumors may be considered at the discretion of the Clinical Trial
Physician
- In addition to the above tumors, Part E will also include participants with metastatic
urothelial carcinoma (mUC).